|Bid||17.32 x 800|
|Ask||22.33 x 1800|
|Day's Range||19.87 - 21.84|
|52 Week Range||16.61 - 39.74|
|Beta (3Y Monthly)||2.06|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2019 - Mar 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.62|
Tenet Healthcare Corporation (THC) established today the pricing of the previously announced private offering of newly issued notes to refinance $1.52 billion of its currently outstanding notes. The offering consists of $1.50 billion aggregate principal amount of senior secured second lien notes due 2027, which will bear interest at a rate of 6.25% per annum, to be issued by Tenet (the “notes”). The size of the offering was increased from the previously announced $750 million aggregate principal amount of notes.
Moody's Investors Service (Moody's) assigned a Ba3 rating to Tenet Healthcare Corporation's ("Tenet") new senior secured second lien notes due 2027. There is no change to Tenet's existing B2 Corporate Family Rating, B2-PD Probability of Default Rating, Ba3 first lien senior secured rating, Ba3 second lien senior secured rating and Caa1 unsecured rating. Proceeds from the new $750 million of senior secured second lien notes will be used in combination with cash to repay its March 2019 unsecured notes at maturity and finance the redemption of its February 2020 unsecured notes.
Tenet Healthcare Corporation (THC) intends to refinance $768 million of its currently outstanding notes by offering to sell $750 million of newly issued notes through a private placement. The offering consists of $750 million in aggregate principal amount of newly issued senior secured second lien notes due 2027 issued by Tenet (the “notes”). Tenet intends to use a portion of the net proceeds from the sale of the notes, after payment of fees and expenses, to fund the redemption and discharge of all $300 million outstanding aggregate principal amount of its 6.75% Senior Unsecured Notes due February 1, 2020.
Tenet Healthcare Corporation and Anthem Blue Cross today announced that they have signed a new multi-year agreement, providing Anthem Blue Cross members with continued in-network access to Tenet’s California facilities and other providers.
# Tenet Healthcare Corp ### NYSE:THC View full report here! ## Summary * Perception of the company's creditworthiness is negative but improving * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for THC with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $5.68 billion over the last one-month into ETFs that hold THC are among the highest of the last year, but the rate of growth is slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Negative The current level displays a negative indicator with a strengthening bias over the past 1-month. Although THC credit default swap spreads are decreasing, they are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness. Please send all inquiries related to the report to firstname.lastname@example.org. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Tenet Healthcare Corporation and Humana Inc. today announced that they have signed a new multi-year agreement, providing Humana members with in-network access to Tenet’s hospitals, outpatient centers and employed physicians.
Trey Abshier will take over next month as the CEO of Central Florida Regional Hospital. Abshier will lead for-profit HCA Healthcare Inc.'s (NYSE: HCA) 221-bed hospital in Sanford. Abshier previously was CEO of Dallas-based Tenet Healthcare Corp.'s (NYSE: THC) Palm Beach Gardens Medical Center in Palm Beach Gardens and CEO of Tenent's Florida Medical Center in Fort Lauderdale.
Tenet Healthcare Corporation will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 8, 2019. Ron Rittenmeyer, Executive Chairman and CEO, will deliver a presentation at the conference at approximately 11:30 a.m.
Health insurer Cigna (NYSE: CI) and Tenet Healthcare Corp. (NYSE: THC) have reached a new agreement that will allow patients at Brookwood Baptist Health to continue receiving in-network coverage from Cigna. Financial terms of the new multi-year agreement were not disclosed. As we've previously reported, Cigna and Tenet had been negotiating a new agreement for a contract that was scheduled to expire at the end of 2018.
Tenet Healthcare Corporation today announced that it has signed a new, multi-year agreement with Cigna Corporation. The agreement provides Cigna members covered under its commercial health plans with uninterrupted in-network access to Tenet providers, including hospitals, outpatient centers and employed physicians.
Health care stocks, traditionally viewed as safe havens during periods of broader market volatility, have pulled back sharply after being the strongest performer in the S&P 500 index in 2018. The Health Care Select Sector SPDR Fund (XLV) exchange-traded fund is the oldest and largest fund in the segment.
HCA Houston Healthcare, part of Nashville, Tennessee-based HCA Healthcare Inc. (NYSE: HCA), named Chris Osentowski as the division's new chief development officer. Osentowski most recently served as the CDO of HCA-affiliated hospital Medical City Plano for a year and has been with HCA Healthcare since 2015, according to a Dec. 20 press release. Prior to joining HCA Healthcare, Osentowski worked with British pharmaceutical company GlaxoSmithKline LLC in Dallas, per the release.
Healthcare took a hit recently on Johnson & Johnson news and a federal judge ruling. The rough trading also spread into the ETF world.
Major stock indexes sold off again Monday. In the Dow Jones today, big decliners included Nike, Goldman Sachs and Johnson & Johnson.
Shares of Johnson & Johnson (NYSE:JNJ) have fallen below their 200-day moving average to return to levels not seen since August, down nearly 13% from the highs seen in early December. Analysts are looking for earnings of $1.95 per share on revenues of $20.2 billion. Gilead Sciences (NASDAQ:GILD) shares are down 16% from the highs set in early October, a double-top high that now sets up a possible violation of the May lows that would put the mid-2017 levels near $60 in play — which would be worth a 10% drop from current levels.
Throwing out ACA as healthcare law in the U.S. would create plenty of tremors within the healthcare industry -- to say nothing of Insurance, Pharmaceuticals and related business sectors.
Hospital stocks like HCA and Medicaid insurer stocks such as Cenente fell sharply Monday folllowing a Friday night ObamaCare ruling striking down the law.
NEW YORK, NY / ACCESSWIRE / December 17, 2018 / Innovate Biopharmaceuticals and Tenet Healthcare Corporation both had high activity days on Friday despite any news from the companies. While shares of Innovate ...
Of the ten analysts covering DaVita (DVA), five have given it “buy” or higher ratings, four have given it “holds,” and one has given it a “sell.”
In the third quarter, DaVita’s (DVA) patient care and other costs rose YoY (year-over-year) to $2.06 billion from $1.95 billion. Its gross margin expanded YoY to 27.52% from 25.41%. Expected trends